Affiliation:
1. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA
Abstract
Serological testing for anti-acetylcholine receptor (AChR) autoantibodies is not only crucial for the diagnosing, disease monitoring, and treatment management of patients with myasthenia gravis (MG) but also for preclinical studies utilizing MG disease models. However, there are no specific guidelines on which methods to use in clinical diagnostic or research laboratories to detect or quantify any MG-specific autoantibodies. Conventional autoantibody assays, particularly those for anti-AChR antibodies, are varied and mostly laboratory-specific. Here, we report our new nonradioactive immunoprecipitation–immunoblotting method for assessing autoantibodies (anti-AChR antibodies) in a mouse model of MG. This simple, efficient, reproducible, and cost-effective assay appears superior to the enzyme-linked immunosorbent assay but comparable to the radioimmunoprecipitation or cell-based assay in specificity and sensitivity. Thus, the newly developed assay can serve as a valuable alternative to classical assays and is suitable for routine testing of AChR-specific autoantibodies in preclinical studies. The further optimization of our assay may facilitate its application in the diagnosis and therapeutic management of patients with MG.
Funder
Association Francaise contre les Myopathies
Myasthenia Gravis Foundation of America, United States
Conquer Myasthenia Gravis
Reference17 articles.
1. Myasthenia Gravis;Gilhus;Nat. Rev. Dis. Primers,2019
2. Koneczny, I., and Herbst, R. (2019). Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells, 8.
3. Clinical Correlations of Antibodies that Bind, Block, or Modulate Human Acetylcholine Receptors in Myasthenia Gravis;Howard;Ann. N. Y. Acad. Sci.,1987
4. Understanding the Burden of Refractory Myasthenia Gravis;Hagenacker;Ther. Adv. Neurol. Disord.,2019
5. Animal Models of Myasthenia Gravis;Christadoss;Clin. Immunol.,2000